Osaka City University, Japan

New data from Japan, the United States and Germany lluminates research in lung cancer

Published in Lab Business Week, November 5th, 2006

Data on lung cancer are outlined in reports from Japan, the United States and Germany.

Study 1: Docetaxel could be considered a therapeutic option for elderly patients with advanced non-small-cell lung cancer (NSCLC).

According to a study from Japan, "Docetaxel has shown activity in elderly patients with advanced NSCLC. This randomized phase III trial evaluated the efficacy and safety of docetaxel versus vinorelbine (the current standard treatment) in elderly patients. Chemotherapy-naive patients age 70 years or older with stage IIIB/IV NSCLC and performance status 2 or lower were eligible."

"Patients randomly received docetaxel...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2006-11-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry